Evolus, Inc. (EOLS)

$12.31

+0.18

(+1.48%)

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $12.05
    $12.40
    $12.31
    downward going graph

    2.11%

    Downside

    Day's Volatility :2.82%

    Upside

    0.73%

    downward going graph
  • $7.44
    $15.43
    $12.31
    downward going graph

    39.56%

    Downside

    52 Weeks Volatility :51.78%

    Upside

    20.22%

    downward going graph

Returns

PeriodEvolus, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
6.12%
6.5%
0.0%
6 Months
1.59%
7.1%
0.0%
1 Year
55.12%
9.8%
0.0%
3 Years
13.47%
14.2%
-20.2%

Highlights

Market Capitalization
770.1M
Book Value
$0.3
Earnings Per Share (EPS)
-1.04
Wall Street Target Price
22.29
Profit Margin
-27.31%
Operating Margin TTM
-12.38%
Return On Assets TTM
-10.69%
Return On Equity TTM
-472.61%
Revenue TTM
219.7M
Revenue Per Share TTM
3.82
Quarterly Revenue Growth YOY
42.199999999999996%
Gross Profit TTM
92.7M
EBITDA
-27.7M
Diluted Eps TTM
-1.04
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.31
EPS Estimate Next Year
0.19
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Evolus, Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 81.07%

Current $12.31
Target $22.29

Technicals Summary

Sell

Neutral

Buy

Evolus, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Evolus, Inc.
Evolus, Inc.
12.94%
1.59%
55.12%
13.47%
-31.27%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
7.56%
2.78%
45.55%
52.55%
67.01%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
7.53%
11.87%
3.28%
23.35%
23.35%
Zoetis Inc.
Zoetis Inc.
5.77%
-5.62%
-5.85%
-9.99%
57.03%
Viatris Inc.
Viatris Inc.
12.75%
-1.42%
12.21%
-15.03%
-28.03%
Catalent, Inc.
Catalent, Inc.
4.08%
11.91%
19.53%
-48.27%
2.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Evolus, Inc.
Evolus, Inc.
NA
NA
NA
-0.31
-4.73
-0.11
NA
0.3
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.75
39.75
0.44
3.99
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.9
29.9
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.62
34.62
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Evolus, Inc.
Evolus, Inc.
Buy
$770.1M
-31.27%
NA
-27.31%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.7B
67.01%
39.75
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$41.0B
23.35%
29.9
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$82.0B
57.03%
34.62
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.2B
-28.03%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.6B
2.08%
211.02
-28.44%

Insights on Evolus, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 60.99M → 59.33M (in $), with an average decrease of 2.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -11.83M → -13.10M (in $), with an average decrease of 10.8% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 39.1%

Institutional Holdings

  • Perceptive Advisors LLC

    9.19%
  • TANG CAPITAL MANAGEMENT LLC

    6.62%
  • BlackRock Inc

    5.21%
  • Morgan Stanley - Brokerage Accounts

    4.86%
  • Nantahala Capital Management, LLC

    4.65%
  • Vanguard Group Inc

    4.64%

Company Information

evolus, inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the united states. it offers jeuveau, a proprietary 900 kilodalton purified botulinum toxin type a formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. the company was founded in 2012 and is headquartered in newport beach, california.

Organization
Evolus, Inc.
Employees
279
CEO
Mr. David Moatazedi
Industry
Health Technology

FAQs